UCBJY: UCB insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
7 institutions reported holding $1.87M of UCB on Form 13F (7 the quarter before). 2 opened a new position and 2 sold out. Shares held by institutions: +31%.
| Largest holders | Shares | Value |
|---|---|---|
| RHUMBLINE ADVISERS | 9,872 | $1.48M |
| GAMMA Investing LLC | 1,824 | $273K |
| ATLAS CAPITAL ADVISORS INC. | 470 | $53K |
| PNC Financial Services Group, Inc. | 271 | $41K |
| Salomon & Ludwin, LLC | 131 | $19K |
| First Command Advisory Services, Inc. | 10 | $1K |
| HANTZ FINANCIAL SERVICES, INC. | 0 | $9 |
Clinical trial readouts
12 Phase 2 or 3 trials by Ucb with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-08-09 | Bimekizumab | Axial Spondyloarthritis | Phase 3 | 508 | Completed | NCT04436640 |
| 2026-08-26 | doxecitine and doxribtimine | Thymidine Kinase 2 Deficiency | Phase 2 | 47 | Completed | NCT03845712 |
| 2026-09-01 | fenfluramine | Dravet Syndrome | Phase 3 | 25 | Completed | NCT06118255 |
| 2026-10-05 | rozanolixizumab | Generalized Myasthenia Gravis | Phase 2/3 | 14 | Completed | NCT06149559 |
| 2026-11-16 (est.) | Zilucoplan | Generalized Myasthenia Gravis | Phase 2/3 | 8 | Recruiting | NCT06055959 |
| 2026-12-21 (est.) | Bimekizumab | Hidradenitis Suppurativa | Phase 3 | 43 | Enrollment complete | NCT06921850 |
| 2027-03-09 (est.) | bimekizumab | Moderate to Severe Plaque Psoriasis | Phase 3 | 89 | Enrollment complete | NCT06506916 |
| 2027-03-29 (est.) | Staccato alprazolam | Stereotypical Prolonged Seizures | Phase 3 | 350 | Recruiting | NCT05077904 |
| 2027-05-06 (est.) | Rozanolixizumab | Myelin Oligodendrocyte Glycoprotein Antibody-associated Dise | Phase 3 | 113 | Enrollment complete | NCT05063162 |
| 2027-05-17 (est.) | Galvokimig | Atopic Dermatitis | Phase 2 | 165 | Enrollment complete | NCT07277660 |
| 2027-10-05 (est.) | rozanolixizumab | Generalized Myasthenia Gravis | Phase 3 | 13 | Enrollment complete | NCT06540144 |
| 2027-10-26 (est.) | Zilucoplan | Generalized Myasthenia Gravis | Phase 3 | 8 | Enrolling by invitation | NCT06435312 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.